Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Exelon
(United States) [Available]Synonyms :
Rivastigmine, Rivastigmina
Class :
Anticholinesterases, Cholinesterase Inhibitors
Brand Name :
Exelon
(United States) [Available]Synonyms :
Rivastigmine, Rivastigmina
Class :
Anticholinesterases, Cholinesterase Inhibitors
Dosage Forms & Strengths
capsule
1.5mg
3mg
4.5mg
6mg
Transdermal patch
4.6mg/24hr
9.5mg/24hr
13.3mg/24hr
Oral- mild-to-moderate Initial dose: 1.5 mg capsule orally every 12hr; increase it up to 1.5 mg/dose every 2 weeks Do not exceed the dose up to 6 mg orally every 12 hours Maintenance dose: 3-6 mg capsule orally every 12 hours Transdermal- mild, moderate, and severe Initial dose: Apply the patch 4.6 mg every 24 hours; increase it up to 9.5 mg every 24 hours minimum 4 weeks; further after additional 4 weeks increase dose up to 13.3 mg patch Mild-to-moderate: 9.5-13.3 mg every 24 hours Moderate-to-severe: 13.3 mg every 24 hours Replace with new patch every 24 hours
Oral- mild-to-moderate
Initial dose: 1.5 mg capsule orally every 12hr; increase it up to 1.5 mg/dose every 2 weeks
Do not exceed the dose up to 6 mg orally every 12 hours
Maintenance dose: 3-6 mg capsule orally every 12 hours
Transdermal- mild, moderate, and severe
Initial dose: Apply the patch 4.6 mg every 24 hours; increase it up to 9.5 mg every 24 hours minimum 4 weeks; further after additional 4 weeks increase dose up to 13.3 mg patch
Mild-to-moderate: 9.5-13.3 mg every 24 hours
Moderate-to-severe: 13.3 mg every 24 hours
Replace with new patch every 24 hours
Oral
Initial dose: 1.5 mg capsule orally every 12hr; increase it up to 1.5 mg/dose every 4 weeks
Maintenance: 1.5-6 mg capsule orally every 12 hours
Transdermal
Initial dose: Apply the patch 4.6 mg every 24 hours; increase it up to 9.5 mg every 24 hours minimum 4 weeks; further after additional 4 weeks increase dose up to 13.3 mg patch
Refer adult dosing
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may decrease the therapeutic effect of anti-parkinson agents
may increase the bradycardic effect of bradycardia-causing agents
may enhance the bradycardic effect of beta blockers
may decrease the therapeutic effect of antiparkinson agents
may decrease the anti-psychotic therapeutic effect
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect of Antipsychotic Agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
clozapine: they may increase the bradycardic effect of Bradycardia-Causing Agents
secretin: they may increase the bradycardic effect of Bradycardia-Causing Agents
sincalide: they may increase the bradycardic effect of Bradycardia-Causing Agents
aclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
cimetropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
glycopyrrolate: they may increase the bradycardic effect of Bradycardia-Causing Agents
ipratropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
levosulpiride: they may increase the bradycardic effect of Bradycardia-Causing Agents
atropine: they may increase the bradycardic effect of Bradycardia-Causing Agents
oxatomide: they may increase the bradycardic effect of Bradycardia-Causing Agents
potassium chloride: they may increase the bradycardic effect of Bradycardia-Causing Agents
revefenacin: they may increase the bradycardic effect of Bradycardia-Causing Agents
tiotropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
umeclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
deferiprone: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
dexamethasone: it may increase the bradycardic effect of Bradycardia-Causing Agents
azelastine: it may increase the bradycardic effect of Bradycardia-Causing Agents
it increases the effect of bradycardia of Beta-Blockers
it increases the effect of bradycardia of Beta-Blockers
it increases the effect of bradycardia of Beta-Blockers
it increases the effect of bradycardia of Beta-Blockers
it increases the effect of bradycardia of Beta-Blockers
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
rivastigmine: they may increase the bradycardic effect of Beta-Blockers
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may increase the bradycardia effect
may decrease the therapeutic effects
may increase the bradycardic effect of beta blockers
metoclopramide decreases the efficacy of antiparkinsonism agents
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of antiparkinson agents
it decreases the efficacy of antiparkinson agents
corticosteroids may increase the risk of adverse effects of acetylcholinesterase Inhibitors
corticosteroids may increase the risk of adverse effects of acetylcholinesterase Inhibitors
corticosteroids may increase the risk of adverse effects of acetylcholinesterase Inhibitors
corticosteroids may increase the risk of adverse effects of acetylcholinesterase Inhibitors
corticosteroids may increase the risk of adverse effects of acetylcholinesterase Inhibitors
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
It may enhance the risk of adverse effects when combined with anticholinesterases
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anti-parkinson agents
hydrocodone/chlorpheniramine/pseudoephedrine
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect
may increase the immunosuppressive effect of corticosteroids
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may increase the toxic effect
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may decrease the therapeutic effect of dipyradimole
may increase the adverse effect of corticosteroids
may increase the toxic effect of corticosteroids
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may increase the bradycardic effect of beta blockers
may decrease the therapeutic effect of anticholinergic agents
acrivastine and pseudoephedrine
may decrease the therapeutic effect of anticholinergic agents
may increase the bradycardic effect of bradycardia-causing agents
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the bradycardic effect of bradycardia-causing agents
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may increase the hypotensive effect of blood pressure lowering agents
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may increase the bradycardic effect of each other
may decrease the therapeutic effect of each other when combined
midodrine: they may increase the bradycardic effect of Bradycardia-Causing Agents
ozanimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
tofacitinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with hormone antagonists
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may have an increased bradycardic effect when combined with other bradycardia-causing agents
amifampridine: they may increase the bradycardic effect of Bradycardia-Causing Agents
dipyridamole: they may increase the bradycardic effect of Bradycardia-Causing Agents
mirabegron: they may increase the bradycardic effect of Bradycardia-Causing Agents
nitroglycerin: they may increase the bradycardic effect of Bradycardia-Causing Agents
succinylcholine: they may increase the bradycardic effect of Bradycardia-Causing Agents
topiramate: they may increase the bradycardic effect of Bradycardia-Causing Agents
fluorouracil: they may increase the bradycardic effect of Bradycardia-Causing Agents
methoxsalen: they may increase the bradycardic effect of Bradycardia-Causing Agents
porfimer: they may increase the bradycardic effect of Bradycardia-Causing Agents
When rivastigmine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
pamidronate: it may enhance the bradycardic effect of Bradycardia-Causing Agents
valerian: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
Actions and Spectrum:
rivastigmine is a medication used to treat cognitive impairments, primarily in Alzheimer’s disease and Parkinson’s disease-related dementia. It works by inhibiting the breakdown of acetylcholine, a neurotransmitter that plays a key role in memory and cognitive function. The actions and spectrum of rivastigmine include:
Cholinesterase Inhibition: rivastigmine is a cholinesterase inhibitor, which means it prevents the breakdown of acetylcholine in the brain. This leads to increased levels of acetylcholine, which can help improve cognitive function.
Symptomatic Relief: It can provide symptomatic relief in Alzheimer’s disease and related dementias by temporarily enhancing cognitive function, such as memory, thinking, and behavior.
Stabilization of Symptoms: rivastigmine may help stabilize or slow down the progression of cognitive decline in some individuals, although it doesn’t cure the underlying diseases.
Mild to Moderate Alzheimer’s Disease: Rivastigmine is typically prescribed for individuals with mild to moderate Alzheimer’s disease.
Parkinson’s Disease Dementia: It is also used in the treatment of cognitive impairment associated with Parkinson’s disease.
Frequency Defined
>10%
Weight loss
Abdominal pain
anorexia
diarrhea
nausea
vomiting
Application site erythema
Agitation
dizziness
headache
falling
Tremor
1-10%
Bradycardia
syncope
Diaphoresis
Dehydration
Decreased appetite
Urinary incontinence
urinary tract infection
Abnormal gait
aggressive behavior
anxiety
Asthenia
bradykinesia
<1%
Atrial fibrillation
atrioventricular block
Dystonia
Post marketing
Tachycardia
Allergic dermatitis
Stevens-Johnson syndrome
urticaria
Severe vomiting
Black Box Warning:
None
Contraindication / Caution:
Contraindications:
Cautions:
Pregnancy warnings:
Pregnancy Category: N/A
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Administration:
It is available in various forms, such as oral capsules, oral solutions, and transdermal patches. The administration of rivastigmine may vary depending on the specific form of the medication:
Oral Capsules or Solutions:
Typically, rivastigmine is taken by mouth with or without food, usually twice a day (morning and evening).
Follow your doctor’s prescribed dosage instructions carefully. The dosage may start low and gradually increase to minimize side effects.
Swallow the capsules whole with a glass of water. If you are using the solution, use the provided measuring device to ensure the correct dose.
Transdermal Patch:
The transdermal patch is applied to the skin.
Clean and dry the skin before applying the patch. Choose an area on the upper or lower back, chest, or upper arm.
Apply the patch once daily and leave it in place for 24 hours.
Rotate the application site to avoid skin irritation.
Patient Information Leaflet
Generic Name: rivastigmine
Pronounciation: riv-uh-STIG-meen
Why do we use rivastigmine?
rivastigmine is used to manage and treat neurodegenerative diseases, specifically dementia, in patients with Parkinson’s and Alzheimer’s diseases. It falls into the category of cholinesterase inhibitors. rivastigmine is a medication that enhances cognitive function by augmenting the levels of a specific natural substance in the brain.
It works as a cholinesterase inhibitor, preventing the degradation of a chemical called acetylcholine, which plays a crucial role in memory, thinking, and reasoning. It doesn’t cure or halt these diseases, but it may enhance memory, cognitive awareness, and the capacity to perform daily activities.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
